Abstract: A novel serological target marker GP73 used for diagnosing and identifying a simple fatty liver and steatohepatitis in populations with fatty liver and a detection application method thereof. The serological target marker GP73 and the application thereof can replace golden standard liver puncture to identify and diagnose the simple fatty liver and steatohepatitis in populations with fatty liver, reduce the detection pain of a patient, and have an extremely high clinical application value in clinically identifying and diagnosing the simple fatty liver and steatohepatitis in the populations with fatty liver and assisting the treatment of the simple fatty liver and steatohepatitis.
Type:
Grant
Filed:
June 19, 2017
Date of Patent:
July 20, 2021
Assignees:
BEIJING DITAN HOSPITAL CAPITAL MEDICAL UNIVERSITY, BEIJING HOTGEN BIOTECH CO., LTD
Abstract: The present invention provides the use of Cimicifugae rhizoma triterpenoid saponin extract, Cimicifugae rhizoma, actein, deoxyactein, or a composition formed by actein and deoxyactein in the preparation of a medicament or a functional health product for autoimmune diseases. The present invention also provides a pharmaceutical composition for autoimmune diseases and a pharmaceutical composition for inhibiting inflammatory cytokines. The invention provides new applications of Cimicifugae rhizoma triterpenoid saponin extract, Cimicifugae rhizoma, actein, deoxyactein, etc., and widens the application field of medicines or functional health products for autoimmune diseases. The raw materials source is plenty, the cost is low, and it has a broad market application value.
Type:
Grant
Filed:
June 13, 2018
Date of Patent:
July 6, 2021
Assignee:
BEIJING DITAN HOSPITAL, CAPITAL MEDICAL UNIVERSITY
Inventors:
Hui Zeng, Xianbo Wang, Liuluan Zhu, Rui Li